Abstract

Anemia is a widespread public health issue, with iron deficiency anemia (IDA) responsible for 50% of cases. This study evaluates the effectiveness of Feroxyl, a ferrous bisglycinate supplement enriched with vitamins, in improving hemoglobin and other blood biomarkers among a cohort of Lebanese patients with ID or IDA. A retrospective chart review of 593 patients showed significant improvements in hemoglobin (1.81 g/dL increase) and biomarkers like MCV, MCH, as well as ferritin after three months of supplementation. Vitamin D also significantly Increased. The supplement was well-tolerated, with mild side effects, making Feroxyl a promising treatment for IDA, particularly in low-resource settings.